Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020 - Cohort Study Based on Administrative Data

Version 1 : Received: 12 November 2021 / Approved: 15 November 2021 / Online: 15 November 2021 (11:50:07 CET)

How to cite: Datzmann, T.; Schmitt, J.; Fuhrmann, S.; Roessler, M.; Meier, F.; Schoffer, O. Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020 - Cohort Study Based on Administrative Data. Preprints 2021, 2021110257 (doi: 10.20944/preprints202111.0257.v1). Datzmann, T.; Schmitt, J.; Fuhrmann, S.; Roessler, M.; Meier, F.; Schoffer, O. Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020 - Cohort Study Based on Administrative Data. Preprints 2021, 2021110257 (doi: 10.20944/preprints202111.0257.v1).

Abstract

(1) Background: Targeted (TT) and immune checkpoint inhibitor (ICI) therapies have become available in the routine care of metastatic melanoma in recent years. (2) Objective: We compared mortality in patients with metastatic melanoma and different systemic therapies. (3) Methods: A retrospective cohort study, based on pseudonymized health insurance data of about 2 million individuals from Saxony, Germany, was conducted for the years 2010 to 2020. Only patients with an advanced stage, i.e. distant metastases were considered for the main analysis. Relative survival since metastasis and predicted survivor curves derived from a Cox model were used to assess potential differences in mortality. (4) Results: Relative survival was highest in the subgroup with sequential use of ICI and TT. All treatments except interferon had significant hazard ratios (HR) in the Cox model with time-dependent effects indicating a protective effect after treatment initiation (HR 0.01-0.146) but decreasing over time (HR 1.351-2.310). The predicted survivor curves revealed best survival under ICI-TT treatment and worst survival under TT treatment alone. (5) Conclusions: We found real-world evidence for survival benefits of patients with metastatic melanoma who received sequential ICI and TT treatment. It is conceivable that the observed high survival differences were overestimated due to bias, such as confounding by indication.

Keywords

metastatic melanoma; targeted therapy; immune checkpoint inhibitor therapy; survival; statutory health insurance data

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.